Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results

JACC: Cardiovascular Interventions

Volumn 9, Issue 3, 2016, Pages 271-277

  Yokoi, Hiroyoshi ^a   Ohki, Takao ^b   Kichikawa, Kimihiko ^c   Nakamura, Masato ^d   Komori, Kimihiro ^e   Nanto, Shinsuke ^f   O'Leary, Erin E ^g   Lottes, Aaron E ^g   Snyder, Scott A ^g   Dake, Michael D ^h  

^a FUKUOKA SANNO HOSPITAL   (Japan)

^b JIKEI UNIVERSITY HOSPITAL   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Nishinomiya Municipal Central Hospital   (Japan)

^g Cook Medical Inc   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drug eluting stent(s); paclitaxel eluting stent(s); peripheral artery disease; peripheral vascular disease; popliteal artery; superficial femoral artery

Indexed keywords

AGED; AMPUTATION; ARTERY DISEASE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DRUG ELUTING CARDIOVASCULAR STENT; DRUG ELUTING STENT; FEMALE; FEMOROPOPLITEAL ARTERY DISEASE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OCCLUSION; PACLITAXEL ELUTING STENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS; CLINICAL TRIAL; FEMORAL ARTERY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; POSTMARKETING SURVEILLANCE; VASCULAR PATENCY;

PACLITAXEL;

AGED; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; VASCULAR PATENCY;

EID: 84977607415     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.09.035     Document Type: Article

References (22)

1. 1 Dake, M.D., Ansel, G.M., Jaff, M.R., et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4 (2011), 495–504.
2. 2 Dake, M.D., Ansel, G.M., Jaff, M.R., et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 61 (2013), 2417–2427.
3. 3 Dake, M.D., Scheinert, D., Tepe, G., et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 18 (2011), 613–623.
4. 4 Jaff, M., Dake, M., Popma, J., Ansel, G., Yoder, T., Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices. Catheter Cardiovasc Interv 70 (2007), 460–462.
5. 5 Schillinger, M., Sabeti, S., Loewe, C., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354 (2006), 1879–1888.
6. 6 Cheng, S.W., Ting, A.C., Wong, J., Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis. Cardiovasc Surg 9 (2001), 133–140.
7. 7 Duda, S.H., Bosiers, M., Lammer, J., et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 16 (2005), 331–338.
8. 8 Cejna, M., Thurnher, S., Illiasch, H., et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 12 (2001), 23–31.
9. 9 Bosiers, M., Deloose, K., Callaert, J., et al. Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 54 (2011), 1042–1050.
10. 10 Ohki, T., Yokoi, H., Kichikawa, K., et al. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials. J Endovasc Ther 21 (2014), 644–653.
11. 11 Iida, O., Takahara, M., Soga, Y., et al. 1-year results of the ZEPHYR registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. J Am Coll Cardiol Intv 8 (2015), 1105–1112.
12. 12 Armstrong, E.J., Saeed, H., Alvandi, B., et al. Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther 21 (2014), 34–43.
13. 13 Lammer, J., Zeller, T., Hausegger, K.A., et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 62 (2013), 1320–1327.
14. 14 Geraghty, P.J., Mewissen, M.W., Jaff, M.R., Ansel, G.M., Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg 58 (2013), 386–395.
15. 15 Tepe, G., Laird, J., Schneider, P., et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 131 (2015), 495–502.
16. 16 Schroeder, H., Meyer, D.R., Lux, B., Ruecker, F., Martorana, M., Duda, S., Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv 86 (2015), 278–286.
17. 17 Micari, A., Cioppa, A., Vadala, G., et al. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. J Am Coll Cardiol Intv 6 (2013), 282–289.
18. 18 Rosenfield, K., Jaff, M.R., White, C.J., et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 373 (2015), 145–153.
19. 19 Tepe, G., Schnorr, B., Albrecht, T., et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. J Am Coll Cardiol Intv 8 (2015), 102–108.
20. 20 Marmagkiolis, K., Hakeem, A., Choksi, N., et al. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv 84 (2014), 555–564.
21. 21 McKinsey, J.F., Zeller, T., Rocha-Singh, K.J., Jaff, M.R., Garcia, L.A., Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. J Am Coll Cardiol Intv 7 (2014), 923–933.
22. 22 Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.